Beyond Oncology: The Surging Demand for Neurological and Autoimmune Solutions in the Modern Antibodies Market
While cancer treatments have historically dominated the biopharma revenue streams, 2026 is seeing a dramatic expansion into the neurology and autoimmune sectors. The success of disease-modifying therapies for Alzheimer’s and Multiple Sclerosis has opened the floodgates for a new class of antibodies designed to cross the blood-brain barrier. This specialized niche requires innovative...
0 Comentários 0 Compartilhamentos 165 Visualizações 0 Anterior